Literature DB >> 10066180

Acetylcholinesterase inhibitors for Alzheimer's disease.

L Flicker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10066180      PMCID： PMC1115069          DOI： 10.1136/bmj.318.7184.615

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  New drug treatment for Alzheimer's disease: lessons for healthcare policy.

Authors:  D Melzer
Journal:  BMJ       Date:  1998-03-07

2.  The International Working Group on Harmonization of Dementia Drug Guidelines: past, present, and future.

Authors:  P J Whitehouse
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

3.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

4.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

5.  Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine.

Authors:  D J Ames; P S Bhathal; B M Davies; J R Fraser; P R Gibson; S Roberts
Journal:  Aust N Z J Med       Date:  1990-04

6.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.

Authors:  N Qizilbash; A Whitehead; J Higgins; G Wilcock; L Schneider; M Farlow
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

7.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

Authors:  W K Summers; L V Majovski; G M Marsh; K Tachiki; A Kling
Journal:  N Engl J Med       Date:  1986-11-13       Impact factor: 91.245
  7 in total
  3 in total

1.  Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

Authors:  P Bentham; R Gray; E Sellwood; J Raftery
Journal:  BMJ       Date:  1999-09-04

Review 2.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.